Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome
| Autor: | Shima Onodera, Shigeki Ito, Yasuhiko Tsukushi, Yusei Aoki, Tatsuo Oyake, Kazunori Murai, Yoji Ishida, Keijiro Suzuki, Takeshi Sugawara, Toshiyuki Uchiyama |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Cancer Research
Antimetabolites Antineoplastic Bone Marrow Cells Kaplan-Meier Estimate Biology Peripheral blood mononuclear cell law.invention 5'-nucleotidase law Deoxycytidine Kinase medicine Humans Clinical significance RNA Messenger 5'-Nucleotidase Polymerase chain reaction Reverse Transcriptase Polymerase Chain Reaction Cytarabine Hematology Deoxycytidine kinase Prognosis Molecular biology medicine.anatomical_structure Real-time polymerase chain reaction Oncology Myelodysplastic Syndromes Leukocytes Mononuclear Bone marrow Precancerous Conditions medicine.drug |
| Zdroj: | Leukemia research. 31(10) |
| ISSN: | 0145-2126 |
| Popis: | We analyzed cytosolic high-Km 5'-nucleotidase (cN-II) and deoxycytidine kinase (dCK) mRNA expression in bone marrow mononuclear cells (BMMNC) of patients with high-risk myelodysplastic syndrome (MDS) using quantitative real-time polymerase chain reaction (rt-PCR). At diagnosis, the cN-II mRNA expression of patients was higher than that of healthy volunteers, but the dCK mRNA expression showed no significant difference. Patients with ara-C-containing chemotherapies whose BMMNC showed a high level of cN-II expression (greater than the median value) had shorter median overall survival (15 months versus 22 months, p0.01) and shorter median post-chemotherapy survival (10 months versus 16 months, p=0.012). These data suggest that the expression level of cN-II mRNA might be a prognostic factor of high-risk MDS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect